Scientists figured out how to strip away the 'sugar shield' that protects cancer cells from immune attacks. Cancer cells are notorious masters of disguise, often coating themselves in a thick layer of sugar-derived molecules known as glycans to remain invisible to the body's natural defenses. This sugary camouflage acts as a physical shield and a molecular 'off switch,' suppressing immune cells and rendering many modern immunotherapies, like checkpoint inhibitors, ineffective. However, researchers from MIT and Stanford University have engineered a breakthrough therapeutic class called 'AbLecs' (antibody-lectin chimeras) specifically designed to strip away this protective barrier and expose hidden tumors. Developed by MIT's Dr. Jessica Stark and Stanford Nobel laureate Dr. Carolyn Bertozzi, AbLecs work by anchoring a glycan-binding lectin protein directly to cancer cells using a tumor-targeting antibody. This molecular pairing prevents the cancer’s sugars from shutting down neighboring immune cells, giving macrophages and natural killer cells the green light to attack. In pre-clinical trials, this plug-and-play platform dramatically reduced lung metastases and outperformed existing antibody drugs, paving the way for adaptable, next-generation immunotherapies that could soon help the estimated 80% of cancer patients who do not respond to current treatments. source: Stark, J. C., & Bertozzi, C. R. (2025). Antibody-lectin chimeras for glyco-immune checkpoint blockade. Nature Biotechnology.